Markets

Arcus Biosciences’ shares surged after promising Phase 1/1b data for its casdatifan-cabozantinib combo in clear cell renal cell carcinoma (ccRCC. The ARC-20 study showed a 46% confirmed overall response rate, exceeding historic benchmarks. Arcus plans Phase 3 trials (PEAK-1) and others evaluating the combination in various ccRCC treatment settings. The positive results highlight the potential to change standards of care for patients whose ccRCC has advanced despite prior immunotherapy treatment.

Xiaomi’s Lu Weibing, following Q1 earnings, discussed future challenges. He emphasized the risks associated with losing touch with core values as the company expands and the need for a scalable management system. External competition wasn’t highlighted; instead, Weibing advocated internal focus, referencing a proverb about self-improvement. Xiaomi’s automotive success further validates its strategy and product strength.

The TROPION-Lung02 and TROPION-Lung04 trials support DATROWAY (datopotamab deruxtecan) combined with immunotherapy as a first-line treatment for advanced NSCLC. TROPION-Lung02 showed a 54.8% objective response rate with DATROWAY and pembrolizumab. Exploratory analyses show promising biomarker associations and the TROPION-Lung04 study found a 57.5% objective response rate when using DATROWAY with rilvegostomig. NeoCOAST-2 data also revealed positive results in the neoadjuvant setting.

Changan Auto differentiates its OTA update strategy from consumer electronics, emphasizing safety and technical complexities. Automotive updates are less frequent, undergo rigorous testing, and handle more complex, interconnected systems. The stakes are higher in vehicles; a glitch can have severe consequences. Changan is developing a comprehensive digital process to manage OTA updates aligned with industrial standards.

Seer and Korea University are collaborating on a large-scale study to discover early cancer biomarkers using Seer’s Proteograph ONE Assay and mass spectrometry. This initiative aims to analyze 20,000 plasma samples to identify novel blood-based biomarkers for improved cancer diagnostics, particularly for young adults. The study, supported by the K-Health MIRAE initiative, utilizes AI-driven analytics, promising accelerated analysis, reduced costs, and the potential for earlier cancer detection and improved patient outcomes.

Following remarks at the Shenzhen auto show comparing product performance, a tech executive ignited online debate on user experience and sales discrepancy. Cryptic responses and fan base clashes ensued, prompting calls for industry leaders to foster mutual respect and collaboration. A commentator emphasized constructive dialogue over public disparagement, recognizing the contributions of Chinese tech companies to innovation.

In the FMCG landscape, a strong online and offline presence is vital. Baixiang’s success in the instant noodle market, holding the top online sales spot, exemplifies this. They achieve this through a synergistic approach: robust e-commerce coupled with strong distributor relationships. Baixiang empowers its distributors with resources, training, and flexible promotions, fostering a symbiotic partnership that fuels their market share growth. This dual-channel synergy enhances responsiveness and market coverage.

Xiaomi’s investment partner, Pan Jiutang, commented on the company’s entry into the EV market. He believes Xiaomi’s presence benefits the industry by driving competition and focusing on consumer needs. Jiutang emphasized their premium electric vehicle strategy, targeting a large market. His comments respond to predictions of Xiaomi’s rapid growth potentially impacting competitors, with significant sales growth expected in the coming years.

Amidst China’s EV price war, automaker executives debate the price-value relationship. GAC emphasizes customer experience and lifecycle cost. BJEV’s chairman stresses profitability challenges, warning against prioritizing short-term gains over quality, safety, and long-term sustainable growth. He critiques unsustainable practices, advocating for innovation, high-end markets, and ethical business conduct, emphasizing customer trust as vital for the industry’s future.

NIO Inc. reported strong May 2025 delivery figures. May deliveries reached 23,231 vehicles, a 13.1% year-over-year increase. Year-to-date deliveries totaled 89,225, up 34.7% year-over-year. Cumulative deliveries reached 760,789 vehicles by the end of May, reflecting growth across its NIO, ONVO, and FIREFLY brands. The company’s strategic expansion targets diverse segments.